RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
鉴定用于卵巢癌预后预测的新型 8-NK 细胞相关基因特征
英文原题：Identifying a Novel Eight-NK Cell-related Gene Signature for Ovarian Cancer Prognosis Prediction.
查看英文原题
Identifying a Novel Eight-NK Cell-related Gene Signature for Ovarian Cancer Prognosis Prediction.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
本研究确定了一个 RiskScore 特征，可将具有不同浸润水平、免疫治疗和化疗药物的患者进行分层。
中文摘要
背景
卵巢癌（OVC）是全球最常见且治疗费用最高的肿瘤之一，总生存期和预后不佳。本研究旨在探索NK 细胞相关基因对 OVC 治疗和预后的价值。
方法
从 TCGA-OVC 数据集（训练集）和 GSE51800 数据集（验证集）获取 RNA-seq 和临床信息。从 immPort 数据集获取 NK 细胞相关基因，并使用 ConsensusClusterPlus 筛选分子亚型；之后通过 LASSO 分析建立风险模型，并通过 CIBERSORT、ssGSEA、ESTIMATE 和 TIDE 算法分析免疫浸润及免疫治疗情况。
结果
基于 23 个与预后相关的 NK 细胞基因，将 TCGA-OVC 样本分为 C1 和 C2 两个亚群。C1 组生存结局更好，免疫浸润增加，肿瘤干细胞也更多。此外，C1 组更适合接受免疫治疗，并且对传统化疗药物敏感。研究构建了 8 基因预后模型，并在 GSE51800 数据集中进行验证。低风险患者免疫细胞浸润水平较高，也更可能从免疫治疗和化疗药物中获益。最后，研究利用列线图和 ROC 曲线验证模型准确性。
结论
本研究确定了一个 RiskScore 特征，可根据患者的免疫浸润、免疫治疗和化疗药物获益情况进行分层，为精确评估 OVC 治疗和预后提供了依据。
展开英文摘要原文
BACKGROUND
Ovarian cancer (OVC) is the most common and costly tumor in the world with unfavorable overall survival and prognosis. This study is aimed to explore the prognostic value of natural killer cells related genes for OVC treatment.
METHODS
RNA-seq and clinical information were acquired from the TCGA-OVC dataset (training dataset) and the GSE51800 dataset (validation dataset). Genes linked to NK cells were obtained from the immPort dataset. Moreover, ConsensusClusterPlus facilitated the screening of molecular subtypes. Following this, the risk model was established by LASSO analysis, and immune infiltration and immunotherapy were then detected by CIBERSORT, ssGSEA, ESTIMATE, and TIDE algorithms.
RESULTS
Based on 23 NK cell-related genes with prognosis, TCGA-OVC samples were classified into two clusters, namely C1 and C2. Of these, C1 had better survival outcomes as well as enhanced immune infiltration and tumor stem cells. Additionally, it was more suitable for immunotherapy and was also sensitive to traditional chemotherapy drugs. The eight-gene prognosis model was constructed and verified via the GSE51800 dataset. Additionally, a high infiltration level of immune cells was observed in low-risk patients. Low-risk samples also benefited from immunotherapy and chemotherapy drugs. Finally, a nomogram and ROC curves were applied to validate model accuracy.
CONCLUSION
The present study identified a RiskScore signature, which could stratify patients with different infiltration levels, immunotherapy, and chemotherapy drugs. Our study provided a basis for precisely evaluating OVC therapy and prognosis.
论文信息
- 作者
- Li N、Yu K、Huang D、Zhou H、Zeng D
- 单位
- Reproductive Medicine Center, Liuzhou Maternity and Child Health Care Hospital, Liuzhou, 545001, China.China
- 期刊
- Current medicinal chemistry2024
- 原文标识
- PubMed 37650393 · DOI 10.2174/0929867331666230831101847